University of Jos Institutional Repository >
Medical Sciences >
Please use this identifier to cite or link to this item:
|Title: ||Serum Lipid and Glucose Profiles in HIV-Positive Nigerian Children|
|Authors: ||Ige, Olukemi O.|
Yilgwan, Christopher S.
Ebonyi, Augustine O.
Yiltok, Esther S.
Cardiovascular disease risk
|Issue Date: ||2017|
|Publisher: ||Journal of Virus Eradication|
|Series/Report no.: ||Vol. 3;Pp 157-162|
|Abstract: ||Objectives: To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine
the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases.
Methods: This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of
the Jos University Teaching Hospital (JUTH) for HIV-positive children and at two primary schools in Jos for HIV-negative
children as controls. One hundred and forty-two HIV-positive children aged 6–18 years and an equal number of controls
were studied by determining their fasting serum lipid and glucose levels. The prevalence of dyslipidaemia and hyperglycaemia
was determined and their risk factors obtained using multivariate logistic regression. P values of less than 0.05 were considered
Results: Mean triglyceride levels were significantly higher in HIV-positive children compared with controls at 87.2 mg/dL
(95% confidence interval [CI] 79.4–95.0) and 68.1 mg/dL (95% CI 62.5–72.7), respectively (P<0.001). There were no
significant differences in mean glucose levels. Dyslipidaemia was significantly higher in HIV-positive children (21.8%)
compared with controls (12.7%; P=0.04). Total serum cholesterol was elevated in 17 (12.0%) HIV-positive participants
compared with seven (4.9%) of controls (P=0.02). Children on lopinavir/ritonavir (LPV/r) and those with no significant
or mild disease had a significantly higher prevalence of hypercholesterolaemia (33.3% vs 4.8% and 14.5% vs 0.0%,
Conclusion: HIV-positive children on antiretroviral (ARV) drugs, especially LPV/r, should have their lipids regularly monitored
as those with dyslipidaemia stand the risk of subsequently developing cardiovascular diseases.|
|Appears in Collections:||Paediatrics|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.